Literature DB >> 1389931

Pharmacodynamics of venlafaxine evaluated by EEG brain mapping, psychometry and psychophysiology.

B Saletu1, J Grünberger, P Anderer, L Linzmayer, H V Semlitsch, G Magni.   

Abstract

1. In a double-blind, placebo-controlled study the effects of venlafaxine--a novel nontricyclic compound inhibiting neuronal uptake of serotonin, noradrenaline and to a lesser extent dopamine--were investigated utilizing EEG brain mapping, psychometric and psychophysiological measures. 2. Sixteen healthy volunteers (eight males, eight females) aged 21-36 years received randomized and at weekly intervals single oral doses of placebo, 12.5 mg, 25 mg and 50 mg venlafaxine. EEG recordings, psychometric and psychophysiological tests, and evaluation of pulse, blood pressure and side-effects were carried out at 0, 2, 4, 6, and 8 h. 3. EEG brain mapping demonstrated that venlafaxine exerted a significant action on human brain function as compared with placebo at all three doses, characterized mostly by attenuation of absolute power, increase of relative delta/theta and beta, and decrease of alpha power, as well as by an acceleration of the total centroid fronto-temporally and by its slowing centrally and parietally. These findings are similar to antidepressants such as imipramine. Topographically, drug-induced alterations were most pronounced over both fronto-temporal and the right temporal to temporo-occipital regions. 4. Psychometric and psychophysiological investigations demonstrated significant dose-dependent psychotropic properties of the drug. Multivariate statistics exhibited an improvement of both the noopsyche (e.g. attention, concentration, attention variability, memory, fine motor activity, reaction time performance) and thymopsyche (e.g. drive, wakefulness)) but also significant psychophysiological activation (e.g. in c.f.f., pupillary and skin conductance measures). 5. Time-efficiency calculations showed significant central effects from the 2nd hour onwards, with increasing differences between placebo and treatment up to the 8th hour. Nausea was the most frequent complaint and appeared dose dependent.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1389931      PMCID: PMC1381350          DOI: 10.1111/j.1365-2125.1992.tb04087.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  27 in total

Review 1.  EEG measures of cerebral asymmetry: conceptual and methodological issues.

Authors:  R J Davidson
Journal:  Int J Neurosci       Date:  1988-03       Impact factor: 2.292

2.  On central effects of serotonin re-uptake inhibitors: quantitative EEG and psychometric studies with sertraline and zimelidine.

Authors:  B Saletu; J Grünberger; L Linzmayer
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

3.  An open-label, dose-finding study of WY-45,030, a novel bicyclic antidepressant.

Authors:  E Schweizer; C Clary; C Weise; K Rickels
Journal:  Psychopharmacol Bull       Date:  1988

4.  Lateralized temporal-limbic dysfunction and psychopathology.

Authors:  P Flor-Henry
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

5.  Dichotic perception: evidence for right hemisphere dysfunction in affective psychosis.

Authors:  A Yozawitz; G Bruder; S Sutton; L Sharpe; B Gurland; J Fleiss; L Costa
Journal:  Br J Psychiatry       Date:  1979-09       Impact factor: 9.319

6.  Systemic structural analysis of the electroencephalogram of depressed patients. General principles and preliminary results of an international collaborative study.

Authors:  C Perris; K Monakhov; L von Knorring; V Botskarev; A Nikiforov
Journal:  Neuropsychobiology       Date:  1978       Impact factor: 2.328

7.  Depression and hemispheric functions: changes associated with unilateral ECT.

Authors:  Z Kronfol; K D Hamsher; K Digre; R Waziri
Journal:  Br J Psychiatry       Date:  1978-06       Impact factor: 9.319

8.  Topographic brain mapping of EEG in neuropsychopharmacology--Part II. Clinical applications (pharmaco EEG imaging).

Authors:  B Saletu; P Anderer; K Kinsperger; J Grünberger
Journal:  Methods Find Exp Clin Pharmacol       Date:  1987-06

9.  [Computer-assisted determination of rigidity in the differentiation of psychopathologic groups].

Authors:  J Grünberger; L Linzmayer; H Stöhr; R Wittek; B Saletu
Journal:  Wien Med Wochenschr       Date:  1988-05-15

10.  An open-label, variable-dose study of WY-45,030 (venlafexine) in depressed outpatients.

Authors:  H L Goldberg; R Finnerty
Journal:  Psychopharmacol Bull       Date:  1988
View more
  9 in total

1.  Diurnal variation in the quantitative EEG in healthy adult volunteers.

Authors:  L Cummings; A Dane; J Rhodes; P Lynch; A M Hughes
Journal:  Br J Clin Pharmacol       Date:  2000-07       Impact factor: 4.335

2.  Differential effects of oxycodone and venlafaxine on resting state functional connectivity-A randomized placebo-controlled magnetic resonance imaging study.

Authors:  Tine M Hansen; Dina Lelic; Anne E Olesen; Asbjørn Mohr Drewes; Jens B Frøkjaer
Journal:  CNS Neurosci Ther       Date:  2018-02-21       Impact factor: 5.243

Review 3.  Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects.

Authors:  G J H Dumont; S J de Visser; A F Cohen; J M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

Review 4.  Venlafaxine extended-release: a review of its use in the management of major depression.

Authors:  K Wellington; C M Perry
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

5.  Comparative pharmacodynamic studies with the novel serotonin uptake-enhancing tianeptine and -inhibiting fluvoxamine utilizing EEG mapping and psychometry.

Authors:  B Saletu; J Grünberger; P Anderer; L Linzmayer; G Zyhlarz
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 6.  Venlafaxine. A review of its pharmacology and therapeutic potential in depression.

Authors:  S M Holliday; P Benfield
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

7.  Quantitative EEG (QEEG) Analysis of Emotional Interaction between Abusers and Victims in Intimate Partner Violence: A Pilot Study.

Authors:  Hee-Wook Weon; Youn-Eon Byun; Hyun-Ja Lim
Journal:  Brain Sci       Date:  2021-04-29

Review 8.  On the Physiological Modulation and Potential Mechanisms Underlying Parieto-Occipital Alpha Oscillations.

Authors:  Diego Lozano-Soldevilla
Journal:  Front Comput Neurosci       Date:  2018-04-04       Impact factor: 2.380

9.  The crossroads of anxiety: distinct neurophysiological maps for different symptomatic groups.

Authors:  Montserrat Gerez; Enrique Suárez; Carlos Serrano; Lauro Castanedo; Armando Tello
Journal:  Neuropsychiatr Dis Treat       Date:  2016-01-18       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.